Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer

BACKGROUND: The presence of hypoxia is a poor prognostic factor in prostate cancer and the hypoxic tumor microenvironment promotes radioresistance. There is potential for drug radiotherapy combinations to improve the therapeutic ratio. We aimed to investigate whether hypoxia-associated genes could b...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:BMC Urol
Main Authors: Bibby, Becky A. S., Thiruthaneeswaran, Niluja, Yang, Lingjian, Pereira, Ronnie R., More, Elisabet, McArt, Darragh G., O’Reilly, Paul, Bristow, Robert G., Williams, Kaye J., Choudhury, Ananya, West, Catharine M. L.
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2021
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8247203/
https://ncbi.nlm.nih.gov/pubmed/34210300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12894-021-00856-x
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares